SCD News Hub
Fulcrum Therapeutics to Present New Clinical Data from the
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast...
Read moreAgios Reports Third Quarter 2025 Financial Results and Provides Business Update
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2025.
Read moreDC sickle cell treatment center sees funding boost
An upgraded center at Howard University Hospital, with new funding from D.C., hopes to better handle patients suffering from sickle cell disease.
Read moreUsing placental growth factor to predict preeclampsia risk in pregnant women with sickle cell disease
In pregnant women with sickle cell disease, the risk of developing early-onset preeclampsia can be determined by measuring levels of a protein associated with placental function and development.
Read moreBiomarker can help predict preeclampsia risk in women with sickle cell disease
In pregnant women with sickle cell disease, the risk of developing early-onset preeclampsia can be determined by measuring levels of a protein associated with placental function and development.
Read moreQuercis Pharma and The Galien Foundation to Spotlight
Quercis will elevate the conversation on sickle cell disease (SCD) at the Galien Patient Summit - highlighting its Prix Galien USA “Best Startup”...
Read moreBridging the gap: sickle cell disease as a case study of paediatric to adult transition in rare disease
The transition from paediatric to adult care increases mortality and worsens outcomes for many young people living with rare diseases like sickle cell disease. EU and national decision-makers must implement holistic and person-centred transition policies for all rare diseases.
Read moreSickle cell disease: Why science needs social responsibility to deliver cures
Sickle cell disease is a genetic disorder causing widespread suffering, particularly in marginalised communities, where access to proven cures is limited by cost and health infrastructure
Read more'I lost two sisters to sickle cell disease
After losing two sisters to sickle cell disease, Adesayo Talabi speaks to the Mirror how she uses grief to break the silence, and push for more Black blood donors across the UK
Read more